This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

Autorentext

Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection.

Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.

Inhalt

1. Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma2. Biology and Pathology of B-cell lymphoma 3. Resistance to Y-90 Ibritumomab Tiuxetan Therapy4. Features of Ibritumomab as Radionuclide Therapy5. Radiological Evaluation of Response and Resistance of Ibritumomab6. Characteristics of Ibritumomab as Radionuclide Therapy Agent7. Resistance and Heterogeneity of Intratumoral Antibody Distribution8. Radiation Dosimetry in Ibritumomab Therapy9. Combining RAIT and immune-based therapies to overcome resistance in cancer?10. Prospects for enhancing efficacy of radioimmunotherapyIndex